BCL2 and acute myeloid leukemia: FLT3-ITD mutations have been shown preclinically to reduce BCL-2 dependence of AML cells and to lead to upregulation of BCL-xL and MCL-1, antiapoptotic proteins that are established to impart resistance to venetoclax [47–53].